Medexus Pharmaceuticals (TSE:MDP) Trading 14.3% Higher

Medexus Pharmaceuticals Inc. (TSE:MDPGet Rating) shares were up 14.3% on Wednesday . The company traded as high as C$1.24 and last traded at C$1.20. Approximately 121,771 shares were traded during mid-day trading, an increase of 367% from the average daily volume of 26,103 shares. The stock had previously closed at C$1.05.

Analysts Set New Price Targets

Separately, Bloom Burton downgraded shares of Medexus Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday.

Medexus Pharmaceuticals Stock Performance

The company has a debt-to-equity ratio of 327.43, a quick ratio of 0.44 and a current ratio of 0.97. The firm has a market cap of C$21.95 million and a P/E ratio of 6.88. The firm’s fifty day moving average price is C$2.32 and its 200 day moving average price is C$2.52.

Medexus Pharmaceuticals (TSE:MDPGet Rating) last released its quarterly earnings data on Wednesday, June 22nd. The company reported C($0.29) EPS for the quarter, beating the consensus estimate of C($0.40) by C$0.11. The business had revenue of C$25.67 million during the quarter, compared to analysts’ expectations of C$21.69 million. Sell-side analysts expect that Medexus Pharmaceuticals Inc. will post 0.05 EPS for the current fiscal year.

About Medexus Pharmaceuticals

(Get Rating)

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. It focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, and allergy. The company's primary products are Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B; and Rupall, a prescription allergy medication.

Further Reading

Receive News & Ratings for Medexus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medexus Pharmaceuticals and related companies with's FREE daily email newsletter.